PubMed

Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.

Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, Mallett V, Norton P, FitzGerald MP, Dandreo KJ, Richter HE, Rozanski T, Albo M, Zyczynski HM, Lemack GE, Chai TC, Khandwala S, Baker J, Brubaker L, Stoddard AM, Goode PS, Nielsen-Omeis B, Nager CW, Kenton K, Tennstedt SL, Kusek JW, Chang TD, Nyberg LM, Steers W; Urinary Incontinence Treatment Network.

Ann Intern Med. 2008 Aug 5;149(3):161-9.PMID: 18678843 [PubMed - indexed for MEDLINE]Related articlesFree article

Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study.

Urinary Incontinence Treatment Network (UITN).

Contemp Clin Trials. 2007 Jan;28(1):48-58. Epub 2006 Jun 18.PMID: 16919506 [PubMed - indexed for MEDLINE]Related articles

Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.

Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E.

Urology. 2004 Aug;64(2):269-74; discussion 274-5.PMID: 15302476 [PubMed - indexed for MEDLINE]Related articles

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z.

JAMA. 2006 Nov 15;296(19):2319-28. Erratum in: JAMA. 2007 Mar 21:297(11):1195. JAMA. 2007 Oct 24;298(16):1864. PMID: 17105794 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.

Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ.

Neurourol Urodyn. 2009;28(1):47-51.PMID: 19089890 [PubMed - indexed for MEDLINE]Related articles

Comparison of fesoterodine and tolterodine in patients with overactive bladder.

Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.

BJU Int. 2008 Nov;102(9):1128-32. Epub 2008 Jul 21.PMID: 18647298 [PubMed - indexed for MEDLINE]Related articles

Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.

Swift SE, Siami P, Forero-Schwanhaeuser S.

Clin Drug Investig. 2009;29(5):305-16. doi: 10.2165/00044011-200929050-00003.PMID: 19366272 [PubMed - indexed for MEDLINE]Related articles

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81.PMID: 19014833 [PubMed - indexed for MEDLINE]Related articles

Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.

Van Kerrebroeck PE, Kelleher CJ, Coyne KS, Kopp Z, Brodsky M, Wang JT.

Health Qual Life Outcomes. 2009 Feb 18;7:13.PMID: 19226471 [PubMed - indexed for MEDLINE]Related articlesFree article

A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT).

Siami P, Seidman LS, Lama D.

Clin Ther. 2002 Apr;24(4):616-28.PMID: 12017406 [PubMed - indexed for MEDLINE]Related articles

Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.

Klutke CG, Burgio KL, Wyman JF, Guan Z, Sun F, Berriman S, Bavendam T.

J Urol. 2009 Jun;181(6):2599-607. Epub 2009 Apr 16.PMID: 19375110 [PubMed - indexed for MEDLINE]Related articles

Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, Roach M, Miklos J, Saltzstein D, Boone T, Staskin DR, Albrecht D; Overactive Bladder: Judging Effective Control and Treatment Study Group.

Mayo Clin Proc. 2001 Apr;76(4):358-63.PMID: 11322350 [PubMed - indexed for MEDLINE]Related articles

A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.

Robinson D, Cardozo L, Terpstra G, Bolodeoku J; Tamsulosin Study Group.

BJU Int. 2007 Oct;100(4):840-5.PMID: 17822465 [PubMed - indexed for MEDLINE]Related articles

Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.

Zinner NR, Mattiasson A, Stanton SL.

J Am Geriatr Soc. 2002 May;50(5):799-807.PMID: 12028164 [PubMed - indexed for MEDLINE]Related articles

Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.

Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.

BJU Int. 2008 Nov;102(9):1133-9. Epub 2008 May 26.PMID: 18510659 [PubMed - indexed for MEDLINE]Related articles

Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).

Sussman D, Garely A.

Curr Med Res Opin. 2002;18(4):177-84.PMID: 12201616 [PubMed - indexed for MEDLINE]Related articles

Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.

Kelleher CJ, Reese PR, Pleil AM, Okano GJ.

Am J Manag Care. 2002 Dec;8(19 Suppl):S608-15.PMID: 12516955 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.

Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, Siegel SW, Tate SB, Jarnagin BK, Rosenblatt PL, Feagins BA.

J Urol. 2009 Sep;182(3):1055-61. Epub 2009 Jul 18.PMID: 19616802 [PubMed - indexed for MEDLINE]Related articles

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

Abrams P, Freeman R, Anderström C, Mattiasson A.

Br J Urol. 1998 Jun;81(6):801-10.PMID: 9666761 [PubMed - indexed for MEDLINE]Related articles

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.

Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, Kell SH; OPERA Study Group.

Mayo Clin Proc. 2003 Jun;78(6):687-95.PMID: 12934777 [PubMed - indexed for MEDLINE]Related articlesFree article